MedTrace Logo

Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation

NCT05837689 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2023-05-01

No results posted yet for this study

Summary

A retrospective analysis to investigate pediatric B-cell acute lymphoblastic leukemia patients who were treated with blinatumomab for consolidation, and who were detected as minimal residual disease (MRD) positive by next generation sequencing (NGS). The efficacy of blinatumomab clearing MRD detected by NGS will be analyzed, in order to see the potential of using NGS to guide MRD eradication by blinatumomab.

Conditions

  • Acute Lymphoblastic Leukemia, Pediatric

Interventions

DRUG

Blinatumomab

IV

Sponsors & Collaborators

  • Xiaojun Xu

    lead OTHER

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-30
Primary Completion
2023-04-30
Completion
2023-04-30
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05837689 on ClinicalTrials.gov